High-precision platforms optimized for Austrian clinical and research laboratory standards.
Austria, particularly the Vienna BioCenter and clusters in Tyrol and Styria, has emerged as a global hub for molecular biology and RNA research. With world-class institutions like the IMBA (Institute of Molecular Biotechnology) and the GMI (Gregor Mendel Institute), the demand for high-throughput, reliable RNA analysis platforms is at an all-time high.
As a leading manufacturer, we understand that Austrian laboratories operate under the highest E-E-A-T standards. Our platforms are designed to integrate seamlessly into the Austrian "Life Sciences Strategy 2023," focusing on precision medicine, oncology, and infectious disease management. We provide the "Information Gain" required for complex transcriptomics, ensuring that Austrian researchers can move from raw data to biological insight with unprecedented speed.
Accuracy Rate
13485 Certified
Local Support
Compliant
Focusing on the 2025-2030 roadmap for European Healthcare digitisation.
Shenzhen BioX Medical Co., Ltd. is a professional manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and clinical laboratory equipment. Established in 2017, the company is headquartered in Shenzhen, China, a leading center for biotechnology innovation, medical device development, and advanced manufacturing.
With a modern manufacturing facility covering more than 9,000 square meters and a workforce of over 200 employees, BioX Medical is dedicated to the research, development, production, and supply of molecular diagnostic technologies for clinical laboratories, hospitals, research institutions, public health organizations, and biotechnology companies worldwide.
The company's product portfolio includes molecular diagnostic analysis systems, nucleic acid testing platforms, genetic analysis systems, pathogen detection solutions, biomarker analysis equipment, automated laboratory testing systems, and precision medicine support technologies. By integrating advanced automation, data management capabilities, and laboratory workflow optimization, BioX Medical develops solutions designed to improve testing efficiency, analytical accuracy, and operational reliability.
Supported by a multidisciplinary team of engineers, laboratory specialists, and quality management professionals, the company continuously invests in innovation and product development. Comprehensive quality control procedures are implemented throughout design, manufacturing, testing, and inspection processes to ensure consistent performance and compliance with international industry standards.
Shenzhen BioX Medical Co., Ltd. serves customers across Europe, North America, Asia-Pacific, the Middle East, Latin America, and Africa. The company also provides flexible OEM and ODM services for distributors, diagnostic companies, and healthcare organizations seeking customized molecular testing solutions.
Our Shenzhen facility utilizes AI-driven load distribution and automated mezzanine platforms to ensure rapid scaling of production for Austrian peak demands.
Leveraging China's integrated biotech supply chain to provide 30-40% more cost-effective solutions compared to local European assemblers without compromising quality.
Every RNA analysis platform undergoes a 72-hour stress test and is calibrated against European reference standards before export to Vienna or Graz.
Committed to advancing modern laboratory technologies, BioX Medical focuses on delivering reliable, scalable, and innovative diagnostic systems that support disease detection, genetic analysis, clinical research, and precision healthcare initiatives. Through continuous technological advancement and customer-oriented development, the company strives to contribute to the global evolution of molecular diagnostics and laboratory medicine.
In the era of the EU In Vitro Diagnostic Regulation (IVDR), compliance is not optional. Our platforms are built from the ground up to meet Austrian medical device standards, ensuring that data privacy (GDPR) and analytical validity are maintained. We provide comprehensive documentation for Austrian hospital tenders (Bundesbeschaffung GmbH - BBG).
Strategic partnerships with Austrian service providers in Vienna and Linz ensure on-site maintenance within 48 hours.
We offer virtual and on-site training for Austrian lab technicians on RT-qPCR and RNA-Seq workflows.
Custom software interfaces localized in German and optimized for Austrian diagnostic protocols.
Expanding the horizon of analytical excellence across various industrial sectors in Austria.
Our platforms are designed following ISO 13485 standards and we provide full technical documentation required for CE-IVD marking under the EU 2017/746 regulation, facilitating smooth adoption in Austrian clinical settings.
Yes, our platforms feature open-API architecture that allows for seamless data flow into standard Austrian LIS providers, ensuring automated results reporting and workflow efficiency.
For standard molecular diagnostic platforms, the lead time is typically 4-6 weeks. We utilize express logistics hubs in Shenzhen to ensure rapid delivery to Austrian customs.
We provide comprehensive remote installation support and have a network of certified technical partners in the DACH region (Germany, Austria, Switzerland) for on-site validation and IQ/OQ/PQ services.
Our analysis platforms are "open-system" friendly, allowing Austrian researchers to use their preferred extraction chemistry while maintaining high analytical sensitivity.
BioX Medical
